Kurma Partners announced it has closed its fourth and largest venture fund, raising €215 million, aimed at backing disruptive therapeutic solutions. The fund’s size and track record were emphasized through prior exits, including acquisitions of Corlieve Therapeutics, Emergence Therapeutics, and Amolyt Pharma. The new vehicle signals continued appetite for early- to mid-stage platform and product-focused biotechs, especially those with clear translational pathways. For portfolio building, larger funds can accelerate follow-on investing and reduce time-to-deploy for selected opportunities. Industry participants will likely watch how Kurma allocates capital across modality types and stages, particularly as biopharma deal terms have leaned on milestones and contingent value structures in recent quarters.